Paramyxoviridae Infections clinical trials

The registry lists 31 studies for Paramyxoviridae Infections across 9 countries. 3 are recruiting or about to start. 19 of them are mainly about Paramyxoviridae Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 3 narrower conditions too, such as Respiratory Syncytial Virus Infections: 478 studies, 69 open.

Get an email when these change. Save the Paramyxoviridae Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 21
Recruiting: 3
Terminated: 2
Status unknown: 2
Withdrawn: 1
Suspended: 1

Phase

Phase 1: 18
Phase 2: 7
Phase 3: 1

Where

United States: 21
Australia: 5
United Kingdom: 3
France: 2
China: 1
Korea, Republic of: 1

Who runs them

National Institute of Allergy and Infectious Diseases (NIAID) (8) · Ansun Biopharma, Inc. (3) · Biota Pharmaceuticals, Inc. (2) · ModernaTX, Inc. (2) · Assistance Publique - Hôpitaux de Paris (2) · University College, London (1) · DiaSorin Molecular LLC (1) · Clover Biopharmaceuticals AUS Pty (1)

Who develops what

Save this set

Every programme with a company-led study here in the last two years, whatever its size: 8 programmes from 4 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

Drug	Leading trial sponsor	Companies, last 5 years	Live now	Given as
SCB-1019TRecent, limited Evidence NCT06984094 · Clover Biopharmaceuticals AUS Pty · Phase 2 · live · comparator · “SCB-1019T” · registered May 2025	—	11 study	11 study	comparator 1

Programmes

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 8 programmes — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programmes. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. Phase 4 trial recorded: a phase 4 study exists somewhere; approval here is not checked. Not read yet: approvals and labels, exclusivity, licences, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Paramyxoviridae Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Oplunofusp	1	1	4
Enzaplatovir	0	0	3
Interferon beta-1a	0	0	1
Interferon Beta-1a Inhalation Solution SNG001	0	0	1

Coming up

1phase 3 study under way

1study finishes main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The study

Mar 2027Study of Safety and PK of AZD0543 in Healthy Adults · AstraZeneca

Who these studies take

Of the 3 Paramyxoviridae Infections studies recruiting now, 2 (67%) set no upper age limit and 1 (33%) stop at 75 or younger. 1 (33%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (33%) take healthy volunteers.

Recruiting studies that take each age, of 3
Age	Women	Men
10	1 (33%)	1 (33%)
18	3 (100%)	3 (100%)
30	3 (100%)	3 (100%)
40	3 (100%)	3 (100%)
50	3 (100%)	3 (100%)
65	2 (67%)	2 (67%)
75	2 (67%)	2 (67%)
85	2 (67%)	2 (67%)

Across all 31 studies, recruiting or not: 58% stop at 75 or younger and 52% at 65; 48% take children; 0% are for women only and 0% for men only; 58% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 31 of 31. search them.